| 17:11 | European ADRs Move Higher in Friday Trading |  |
| 15:17 | Inovio Pharmaceuticals Says Brain Cancer Combination Therapy Produced Immune Response i.. | |
| 26/05 | Sanofi - European Week Against Cancer 2022 - Interview with Santiago Aguirre, Market Le.. | |
| 26/05 | SANOFI : FDA approves Dupixent® (dupilumab) as first treatment for adults and children age.. | |
| 25/05 | French health body backs new COVID vaccine booster campaign for this autumn | |
| 23/05 | Fitch Raises Sanofi's Outlook To Positive From Stable on Transition Plan, Profitability | |
| 23/05 | BOLSA DE MADRID : Un punto bajo que cae |  |
| 23/05 | France's Sanofi Wins US FDA Nod for Eosinophilic Esophagitis Drug | |
| 20/05 | Regeneron, Sanofi Receive US FDA Approval of Dupixent for Eosinophilic Esophagitis | |
| 20/05 | PRESS RELEASE : FDA approves Dupixent® (dupilumab) as first treatment for adults and child.. | |
| 20/05 | PRESS RELEASE : FDA approves Dupixent® (dupilumab) as first treatment for adults and child.. | |
| 20/05 | Sanofi's Dupixent wins U.S. approval for bigger use | |
| 20/05 | FDA Grants Regeneron Approval for Dupixent in Inflammatory Disorder Treatment | |
| 20/05 | SECTOR UPDATE : Health Care Stocks Gain Premarket Friday | |
| 20/05 | Sanofi's Xenpozyme Secures Positive Opinion From the European Medicines Agency's CHMP | |
| 20/05 | BOLSA DE MADRID : La mini tabla de salvación es china | |
| 18/05 | TRANSCRIPT : Sanofi - Special Call | |
| 17/05 | Sanofi Announces New Nirsevimab Data Analyses Reinforce Efficacy Against RSV | |
| 17/05 | ASCO - New data from fast-growing innovative Oncology pipeline and portfolio to be pres.. | |
| 17/05 | MARKETSCREENER'S WORLD PRESS REVIEW : May 17, 2022 | |
| 17/05 | Unilever, Uber, Zurich Call For 2035 Ban On Combustion Engines In Europe | |
| 16/05 | Sanofi - Sarclisa (isatuximab) combination provides unprecedented median progression fr.. | |
| 16/05 | Sarclisa® (isatuximab) combination provides unprecedented median progression free surv.. | |
| 16/05 | Sanofi Says Multiple Myeloma Combination Therapy Shows Longer Progression-Free Survival.. | |
| 16/05 | BOLSA DE MADRID : Aterrizaje brusco en China | |
| 16/05 | Sanofi To Appeal French Court Ruling To Compensate Family For Epilepsy Drug Side Effect.. | |
| 16/05 | Sanofi Says Phase 3 Study of Sarclisa Showed Longer Progression-Free Survival | |
| 16/05 | Sanofi's Blood Cancer Drug Prolongs Progression-free Survival By 36 Months In Late-stag.. | |
| 15/05 | PRESS RELEASE : Sarclisa® (isatuximab) combination provides unprecedented median progressi.. | |
| 15/05 | Sarclisa® Combination Provides Unprecedented Median Progression Free Survival in Patien.. | |
| 15/05 | PRESS RELEASE : Sarclisa® (isatuximab) combination provides unprecedented median progressi.. | |
| 11/05 | Sanofi Says Nirsevimab Showed Nearly 80% Efficacy Against Respiratory Syncytial Virus | |
| 11/05 | Sanofi-AstraZeneca's Respiratory Syncytial Virus Drug Shows 80% Efficacy in Pooled Data.. | |
| 11/05 | PRESS RELEASE : New nirsevimab data analyses reinforce efficacy against RSV | |
| 11/05 | PRESS RELEASE : New nirsevimab data analyses reinforce efficacy against RSV | |
| 10/05 | European Stocks Rebound As Volatility Continues to Dominate Markets | |
| 10/05 | Rallybio Secures Global Rights to Sanofi's Antibody Candidate to Treat Anemia | |
| 10/05 | Acerus Pharmaceuticals Reports Q1 Total Revenue of US$0.8 Million; Company Update and O.. | |
| 09/05 | IGM Biosciences Announces Closing of Global Collaboration Agreement with Sanofi | |
| 06/05 | Igm Biosciences, Inc. Announces Closing of Global Collaboration Agreement with Sanofi | |
| 06/05 | EuroAPI gains on market debut after spin-off from Sanofi | |
| 06/05 | Sanofi Spinoff EUROAPI Gains 5% in Euronext Paris Debut | |
| 06/05 | BOLSA DE MADRID : Don't Look Up | |
| 04/05 | Regeneron's COVID drug sales outside U.S. help revenue beat | |
| 04/05 | Will The Supreme Court Take The Bait? CVSG Issued And Other Updates In The Amgen v. San.. | |
| 04/05 | FOUNDATION S : Sanofi's new philanthropic spearhead | |
| 04/05 | PRESS RELEASE : Foundation S: Sanofi's new philanthropic spearhead | |
| 03/05 | Annual General Meeting of May 3, 2022 | |
| 03/05 | PRESS RELEASE : Annual General Meeting of May 3, 2022 | |
| 03/05 | PRESS RELEASE : Annual General Meeting of May 3, 2022 | |
| 03/05 | Sanofi Appoints Approves Appointment of Carole Ferrand, Emile Voest and Antoine Yver as.. | |
| 03/05 | Sanofi Approves Cash Dividend, Payable on May 10, 2022 | |
| 03/05 | TRANSCRIPT : Sanofi - Shareholder/Analyst Call | |
| 02/05 | Denali Therapeutics, Sanofi Start Phase 2 Trial for ALS Inhibitor | |
| 02/05 | L'agenda di domani |  |
| 02/05 | L'agenda della settimana | |
| 29/04 | SANOFI : teams up with McLaren Racing to accelerate industrial excellence - Form 6-K | |
| 29/04 | L'agenda della prossima settimana | |
| 29/04 | Sanofi Teams Up with Mclaren Racing to Accelerate Industrial Excellence | |
| 28/04 | SANOFI : Q1 2022 business EPS(1) up 16.1% at CER driven by higher sales and improving marg.. | |
| 28/04 | Strong earnings spur rally across European stocks | |
| 28/04 | BioMarin Announces Record Revenues in First Quarter 2022 | |
| 28/04 | TRANSCRIPT : Sanofi, Q1 2022 Earnings Call, Apr 28, 2022 | |
| 28/04 | SANOFI : supera las expectativas del consenso y confirma los objetivos para 2022 | |
| 28/04 | SANOFI : Q1 Earnings Snapshot | |
| 28/04 | Sanofi mit überraschend starkem Jahresauftakt |  |
| 28/04 | Sanofi's Q1 Adjusted Earnings, Revenue Rise; Reaffirms 2022 Guidance | |
| 28/04 | Sanofi Confident In Full-Year Prospects As Dupixent, Consumer Healthcare Drive Strong F.. | |
| 28/04 | BOLSA DE MADRID : La venganza de Meta | |
| 28/04 | Sanofi Earnings, Sales Rose in 1Q; Expects Further Growth in 2022 | |
| 28/04 | Sanofi steigert Umsatz und Ergebnis | |
| 28/04 | INTERIM REPORT Q1/2022 : Our financial targets remain in place | |
| 28/04 | Sanofi ziet omzet stijgen |  |
| 28/04 | Sanofi profit gain beats market view on bestseller drug Dupixent | |
| 28/04 | Sanofi's Q1 Profit Soars Over Dupixent's Sustained Performance, Higher Consumer Healthc.. | |
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Italiano
Nederlands (Nederland)
Nederlands (België)
bourse
Rapport
